US$15.47-0.8%11月13日 收盘
数据截至2026年8月31日，来自2026年10月13日提交的10-Q
Nurix licenses rights to experimental cancer drugs and protein-degradation research to pharmaceutical companies, while developing its own cancer and immune-disease medicines.
截至 2026年8月31日 的季度，与去年同季度相比。
| 指标 | 截至该日的 3 个月2026年8月31日 | 截至该日的 3 个月2025年8月31日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$673.1M | US$7.9M | +8,426.27% |
| 利润 | US$549.8M | -US$86.4M | +736.20% |
| 每股收益 | US$4.73 | -US$1.03 | +559.22% |
| 自由现金流 | US$614.2M | -US$60.1M | +1,122.10% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
“The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
公告在开盘前或收盘后发布，因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况，反应都包含在内。
(NX-5948) Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche across malignant hematology, immunology and neurology. Bexobrutideg is currently being evaluated in a broad clinical development program in patients with CLL, including DAYBreak CLL-201 (NCT07221500), a pivotal single-arm Phase 2 study in relapsed/refractory CLL; DAYBreak CLL-306 (NCT07516093), a randomized Phase 3 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL; NX-5948-203 (NCT07520006), a Phase 1b/2 study evaluating bexobrutideg in combination with venetoclax with or without an anti-CD20 antibody in relapsed/refractory and treatment-naïve CLL; and NX-5948-301 (NCT05131022), a Phase 1a/1b study in relapsed/refractory B-cell malignancies. Additional information about these clinical trials can be found at clinicaltrials.gov.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Nurix Therapeutics, Inc. 于 2026年10月13日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
暂无 Nurix Therapeutics, Inc. 的业绩电话会文字记录。
Results released 2026年10月13日, before the market closed
Shares were essentially flat as Roche financing and Phase 3 progress were offset by one-off-heavy earnings and the discontinued NX-2127 program.
Into the report: -11.7% over a month, -3.6% over three months, -20.3% from the year's high.
Written by AI on 2026年10月23日 from Nurix Therapeutics, Inc.'s results releases, earnings call and SEC filings; every quote it relied on was checked against them. It describes the report, it is not investment advice, and it is in English only.